GHRP-6: The Appetite Claim With No Human Trial Behind It

GHRP-6 is bought for appetite, and no human trial of GHRP-6 and appetite exists. The canonical study injected the peptide directly into rat brains. What GHRP-6 demonstrably does in people is raise cortisol and ACTH across the whole night.

That gap between reputation and record is unusually wide for a compound this old. GHRP-6 was first given to humans in 1990, sits on FDA's Category 2 list (503B) of bulk substances that may present significant safety risks, and is the cheapest of the four ghrelin-receptor agonists tracked in the growth hormone peptides category at a median $3.90/mg. For per-injection volume, use the peptide dosing calculator alongside the reconstitution calculator.

What is GHRP-6, and how does it differ from hexarelin?

GHRP-6 is a synthetic hexapeptide — His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂, CAS 87616-84-0, formula C₄₆H₅₆N₁₂O₆, molecular weight 873.0 g/mol — that agonises the ghrelin receptor GHS-R1a and also binds CD36. It carries the developer code SKF 110679 and is the structurally simplest member of its class. Hexarelin is the same hexapeptide plus one methyl group, which places the two molecules 14.0157 daltons apart. That single difference is invisible to HPLC and trivial for mass spectrometry.

Unlike GHRP-2, GHRP-6 contains no unnatural amino acids — all natural residues, with two in D-configuration.

Three database caveats are worth knowing, because they propagate into vendor listings. PubChem's main GHRP-6 record carries no CAS number; the compound appears under two duplicate CIDs; and the synonym list for CID 4345065 erroneously includes "GHRP-2 Acetate". If you are checking a vendor's identity claims against PubChem, verify against formula and mass rather than trusting a name string.

Does GHRP-6 increase appetite in humans?

No human trial has ever tested it. The single canonical citation for GHRP-6 and appetite is Locke et al. (Life Sciences, 1995), which delivered the peptide intracerebroventricularly in rats — directly into the cerebral ventricles, bypassing everything between a vial and the hypothalamus. We searched for human GHRP-6 appetite data and found none. That is an absence of evidence rather than evidence of absence, but it is the honest state of the record.

Read the paper's own title: Locke et al., "Intracerebroventricular growth-hormone-releasing peptide-6 stimulates eating without affecting plasma growth hormone responses in rats". Rats. Intracerebroventricular.

The finding is genuinely interesting on its own terms: the feeding effect is centrally mediated and dissociable from GH release. That is a mechanism paper about brain circuitry. It is not evidence that subcutaneous GHRP-6 increases appetite in people, and it was never presented as such.

The only human appetite trial for any compound in this class is GHRP-2 in ten children — seven of ten reporting increased appetite over the first six months, with no significant BMI change.

The appetite effect may well be real. Ghrelin biology makes it plausible and community reports are consistent. But "plausible and widely reported" is a different claim from "demonstrated", and this article will not present the second when only the first is available.

What does GHRP-6 do to growth hormone in humans?

GHRP-6 raises growth hormone dose-dependently in healthy men, and it does so synergistically with GHRH. Bowers et al. (JCEM, 1990) gave 18 normal men intravenous boluses of 0.1–1.0 µg/kg and measured that synergy — the finding that established the two-receptor rationale still used to justify GHRH-plus-secretagogue stacking today. Prolactin, LH, TSH and cortisol were measured as specificity checks, and at these low doses the paper frames GHRP-6 as GH-specific. Mild facial flushing was reported.

The human dataset behind that statement is small: three studies in total, only one of which is widely cited.

The 1990 result is the strongest thing GHRP-6 has. It is also acute, intravenous and low-dose — three qualifiers that matter, because the specificity conclusion does not survive the second human study.

Does GHRP-6 raise cortisol and ACTH?

Yes, and it was measured across a full night in humans. Frieboes et al., "Growth Hormone-Releasing Peptide-6 Stimulates Sleep, Growth Hormone, ACTH and Cortisol Release in Normal Man" (Neuroendocrinology, 1995) gave healthy male controls repetitive intravenous GHRP-6 boluses versus placebo with EEG and hormone monitoring from 23:00 to 07:00. GH and ACTH rose significantly in the early morning hours, and cortisol was substantially elevated across the whole night, particularly the first half.

Sleep architecture changed too, but not in the direction the marketing implies. Stage 2 sleep increased; slow-wave sleep did not change. Deep sleep was unaffected.

So the HPA-axis effect is real, measured in humans, and it happens overnight — which is when most community protocols dose.

Oliveira et al. (Journal of Endocrinological Investigation, 2003) reported that GHRP-6 stimulates cortisol and ACTH release in patients with Cushing's disease. We confirmed the citation but could not retrieve its results, so no figures are quoted here.

Note the tension between the 1990 and 1995 studies. At low intravenous doses GHRP-6 looked GH-specific; with repetitive nocturnal dosing it clearly was not. Dose and pattern probably matter, and nobody has mapped that curve in humans.

Does GHRP-6 raise prolactin?

The prolactin claim is commonly asserted and not established. We found no primary human result quantifying a prolactin rise from GHRP-6. Frieboes measured GH, ACTH and cortisol — not prolactin. The 1990 first-in-man study did measure prolactin, as one of four specificity checks, and reported specificity at the doses used. So the one human dataset that looked found nothing to report, and the study people cite for the claim never measured it.

Treat the prolactin claim as unsupported until someone produces the measurement. That is a narrower statement than "GHRP-6 does not raise prolactin" — a higher-dose or chronic study might find one. It has not been run.

What does the CD36 research actually show?

GHRP-6 binds CD36 in addition to GHS-R1a, and that second receptor underpins a substantial Cuban research programme on cytoprotection and wound healing. All of it is animal work. Mendoza Marí et al. (Plastic Surgery International, 2016) studied Wistar rats and rabbit ears, and reported that GHRP-6 "showed no effect on the reversion of consolidated lesions" — it helped fresh wounds, not established ones. No human cytoprotection or cardiac trial exists.

More recent work in Pharmaceuticals (March 2026) reported that GHRP-6 at 0.4 mg/kg intraperitoneally for seven days attenuated myocardial damage and interstitial fibrosis in rats after permanent coronary ligation, with proteomic evidence of upregulated fatty-acid β-oxidation.

This is real and interesting research. It is also entirely animal, at intraperitoneal doses, in acute injury models — and the route matters as much here as it does with the appetite data.

Claims versus evidence

Of the nine claims routinely made for GHRP-6, two are established in humans: GH release and the cortisol/ACTH rise. The appetite claim it is mostly bought for rests on rats dosed intracerebroventricularly. The prolactin claim has no primary human measurement behind it. The cardioprotective and wound-healing claims are animal only. And there is no chronic human dosing study at any dose, which leaves long-term safety genuinely unknown rather than merely unproven.

Is GHRP-6 approved or legal anywhere?

GHRP-6 is not approved in any jurisdiction, and it is one of the few peptides FDA has kept on its Category 2 list (503B) of bulk substances that may present significant safety risks. It was added on 29 September 2023, and the page remained current as of 22 April 2026. The contrast with its own sibling is instructive: GHRP-2 came out of the same Bowers research programme and is licensed in Japan as a diagnostic agent. GHRP-6 is licensed nowhere.

FDA's stated rationale is notable because the agency itself names the cortisol issue:

"Compounded drugs containing GHRP-6 may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities. FDA has identified limited safety-related information, but the available data reveal safety concerns including potential effect on cortisol and increase in blood glucose due to decreases in insulin sensitivity."

GHRP-6 remained on that list through the April 2026 reclassification, when sixteen other substances came off. The reason was procedural: those nominations were withdrawn by their nominators, and nobody withdrew GHRP-6's. It was not on the July 23–24, 2026 PCAC agenda either. See our FDA peptide regulation timeline.

WADA 2026: GHRP-6 is named explicitly at S2.2.4 under GH-releasing peptides, prohibited at all times, non-specified.

How is GHRP-6 dosed, and what validates that?

No validated protocol exists. Every published human dose of GHRP-6 is intravenous and acute: 0.1–1.0 µg/kg IV bolus in the 1990 study, and repetitive IV boluses in the 1995 sleep study. The community convention of 100–300 mcg subcutaneously two or three times daily has no trial behind it at all — not a dose-ranging study, not a saturation curve, not a single subcutaneous pharmacokinetic paper we could locate.

Two practical points follow from the actual data rather than the convention.

First, the cortisol elevation was measured with nocturnal dosing — the pattern most community protocols use. The one human study of overnight GHRP-6 is the one that found cortisol raised across the night.

Second, no chronic human study exists at any dose, so nothing is known about what months of exposure do to the HPA axis or to insulin sensitivity, which is precisely what FDA flags in the quotation above. Reduce or stop if glucose control deteriorates, since that is the mechanism the agency named.

For reconstitution arithmetic and per-injection volume, use the peptide dosing calculator and the peptide dosage guide.

How do you tell GHRP-6 from hexarelin in a vial?

Only mass spectrometry separates them. GHRP-6 and hexarelin differ by a single methyl group — 872.4446 against 886.4602 monoisotopic, a gap of 14.0157 Da. Both are hexapeptides with two indole chromophores, near-identical UV absorbance and closely similar chromatographic retention, so an HPLC-UV certificate cannot distinguish them. Mass spectrometry does so trivially. The commercial incentive runs one way: hexarelin sells for more than twice as much per milligram, so the substitution favours hexarelin vials containing GHRP-6.

A 14 Da discrepancy on a certificate deserves scrutiny rather than a shrug, in either direction, since it is also the shift produced by common methylation artefacts. Acetate salt forms add roughly 60 Da per acetate to the weighed material without changing the peptide ion — a routine source of certificate confusion that is separate from the hexarelin problem.

The Purity Index records GHRP-6 at 99.35 across 44 recency-weighted tests from 11 laboratories (verified August 2026), against a platform composite of 99.50. GHRP-6 price data shows 13 shops in stock, median $3.90/mg, lowest $1.50/mg (verified August 2026). Those figures exclude shipping, taxes and customs, coupon codes, bulk tiers, multi-vial kits and account-gated pricing.

Peptigrity tracks 530 shops and 11,852 independent lab tests across 118 peptides, with 1,283 community reviews (verified August 2026), and weights community reviews and independently verified purity equally in every trust score. See mass spectrometry for peptides, how to read peptide lab test results, how to verify peptide quality before you buy and the GHRP-6 compound page.

How does GHRP-6 compare with the rest of its class?

GHRP-6 is the only compound of the four where the signature claim has no human trial. GHRP-2 is approved in Japan as a diagnostic and its GH effect is validated in 135 subjects. Hexarelin's cardioprotection claim rests on animal receptor data, with the human effect absent in diseased hearts. Ipamorelin's selectivity was demonstrated in swine. Each of those is a limited claim with a locatable study behind it; GHRP-6's appetite claim has rats and a hole in the skull.

For the three-way head-to-head, see GHRP-2 vs GHRP-6 vs ipamorelin.

The trial that would settle this

One study design would resolve most of what is unknown about GHRP-6: subcutaneous dosing, repeated over months, with measured energy intake as the primary endpoint and cortisol, ACTH, glucose and insulin sensitivity as safety measures. Every human GHRP-6 dose on record is intravenous and acute. Every appetite result is intracerebroventricular and in rats. Nothing about that combination tells a buyer what happens when a person injects 100–300 mcg under the skin three times a day for a year.

Frequently Asked Questions

Does GHRP-6 actually increase appetite?

No human trial has tested it. The canonical study injected the peptide directly into rat brains, which established that the effect is centrally mediated and separable from GH release but says nothing about subcutaneous dosing in people. Community reports are consistent, and consistent anecdote is not evidence.

Does GHRP-6 raise cortisol?

Yes. Measured across a full night in healthy men, cortisol was substantially elevated, particularly in the first half of the night, alongside ACTH. FDA cites the cortisol effect in its own Category 2 rationale, together with a possible increase in blood glucose from reduced insulin sensitivity.

Does it improve sleep?

It increased stage 2 sleep in the one human study that measured it. Slow-wave (deep) sleep did not change — the opposite of what most sleep-related marketing implies. No study has looked at what repeated subcutaneous dosing does to sleep architecture.

Is GHRP-6 approved anywhere?

No. Its sibling compound GHRP-2, from the same research programme, is approved in Japan as a diagnostic agent. GHRP-6 is approved nowhere, sits on FDA's Category 2 list, and is prohibited in sport at all times.

Can it be mistaken for hexarelin?

Yes, on HPLC — the two differ by one methyl group, 14 Da, and co-elute closely with near-identical UV absorbance. Only mass spectrometry distinguishes them. Since hexarelin sells for more than twice as much per milligram, the commercial incentive runs toward hexarelin vials containing GHRP-6.

Is it banned in sport?

Yes. GHRP-6 is named at WADA S2.2.4 under growth hormone-releasing peptides, prohibited at all times and classified as non-specified. That applies in and out of competition, regardless of dose.

Where GHRP-6 sits

GHRP-6 is the oldest and simplest compound in its class, and the distance between what it is known to do and what it is bought for is unusually wide. Its GH release is real and was demonstrated in 1990. Its cortisol effect is real and was demonstrated in 1995. Its appetite effect — the reason most buyers choose it over the alternatives — has been demonstrated in rats, via a route that involves a hole in the skull.

Thirty-five years after the first human study, nobody has run the trial that would answer the question the compound is actually sold on. That is not a reason to conclude the appetite effect is fictional. It is a reason to stop quoting it as though someone had checked.

The cheapest compound in a category is often cheap because it is old and easy to make. GHRP-6 is both. It is also, on the current record, the one whose defining property is the least examined.

Browse the growth hormone peptides category, or our complete peptide guide with 118 compounds (verified August 2026). For per-injection volume, use the peptide dosing calculator alongside the reconstitution calculator. Compare shops through independent lab tests and community-verified shop reviews.

This article is for educational and informational purposes only and does not constitute medical advice. Peptides discussed may be investigational compounds not approved by the FDA (or equivalent regulators in your jurisdiction) for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.